Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
NCT02493322 · EMS · PHASE3 · withdrawn · last registry update 2025-12-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Decided by Sponsor” | – | Registry record, EMS |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-26Also stopped (withdrawn): Eurofarma Laboratorios S.A., N0877 + Benicar HCT ® Tablets 40 mg/25 mg (NCT06608472)
- 2026-09-24Also stopped (terminated): Milton S. Hershey Medical Center, Angiotensin-(1-7) + Saline (NCT05301192)
- 2026-09-18Phase 3 first posted: Martin Blomberg Jensen, empagliflozin (Jardiance) 25 mg + Losartan 100 mg (NCT07828002)
- 2026-07-02Results posted on the registry: University of New Mexico, Angiotensin II (NCT05824767)
- 2026-05-14Phase 3 first posted: Dr Mudassar Saeed Pansota, ARBs alone + ARBs in combination of SGLT2i (NCT07586371)
- 2026-05-06Phase 3 first posted: Washington University School of Medicine, HFrEF Polypill (NCT07569640)
- 2026-04-30Results posted on the registry: Alnylam Pharmaceuticals, Zilebesiran + Placebo (NCT06423352)
- 2026-04-13Results posted on the registry: Northwestern University, Angiotensin II + Placebo (NCT04904562)
- 2026-04-13Also stopped (terminated): Northwestern University, Angiotensin II + Placebo (NCT04904562)
- 2026-01-14Results posted on the registry: OHSU Knight Cancer Institute, Capecitabine + Fluorouracil (NCT04539808)
- 2026-01-13Also stopped (terminated): University of California, San Francisco, Anti-hypertensive agent: amlodipine + Anti-hypertensive agent: Chlorthalidone (NCT05370599)
- 2025-12-08Also stopped (withdrawn): EMS, Olmesartan medoxomil 40mg + chlorthalidone 12,5mg + Olmesartan medoxomil 40mg + chlorthalidone 25mg (NCT02483936)
- 2025-11-20Results posted on the registry: Travere Therapeutics, Inc., Sparsentan (NCT05856760)
- 2025-09-18Phase 3 first posted: Alnylam Pharmaceuticals, Zilebesiran + Placebo (NCT07181109)
- 2025-08-24Results posted on the registry: Wake Forest University Health Sciences, Angiotensin II (NCT03733145)
- 2025-07-22Results posted on the registry: University of Alabama at Birmingham, Perindopril + Losartan (NCT03295734)
- 2025-07-10Results posted on the registry: Anna Stanhewicz, PhD, Losartan Potassium + Placebo (NCT04632589)
- 2025-07-09Results posted on the registry: Alnylam Pharmaceuticals, Indapamide + Amlodipine (NCT05103332)
- 2025-07-02Results posted on the registry: University of Texas Southwestern Medical Center, a drug against AGTR1 (NCT03354143)
- 2025-06-04Also stopped (terminated): University of Arizona, Angiotensin-(1-7) + Placebo for Angiotensin-(1-7) (NCT03252093)
- 2025-06-04Also stopped (suspended): University of Arizona, Angiotensin-(1-7) (NCT03159988)
- 2025-06-03Results posted on the registry: University of Iowa, Salsalate Oral Tablet + Placebo Oral Tablet (NCT03482440)
- 2025-02-25Results posted on the registry: Arbor Pharmaceuticals, Inc., Azilsartan Medoxomil Low-dose + Losartan (NCT02235909)
- 2025-02-18Results posted on the registry: Ionis Pharmaceuticals, Inc., Placebo + IONIS-AGT-LRx (NCT04714320)
- 2025-01-31Results posted on the registry: Vicore Pharma AB, C106 solution + Placebo (NCT05427253)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision